A novel plasma membrane proteins-related prognostic model for luminal breast cancer

doi:10.3969/j.issn.1009-976X.2021.03.006

Abstract

Abstract: Objective Plasma membrane proteins （PMPs） play an indispensable role in tumor development and progression. Luminal breast cancer is the most common molecular subtype of breast cancer seriously threatening the health of women, which makes it crucial to construct a more accurate prognostic model and find out precise therapeutic targets to improve the prognosis for luminal breast cancer patients. Methods We downloaded conforming transcriptome RNA-sequencing data and their clinical information about luminal breast cancer from TCGA database as a training set. After identifying differentially expressed plasma membrane proteins-related genes, we screened out the prognostic genes for further analysis. And we downloaded relevant data from GEO database and processed them as a validation set. Results A prognostic model was constructed. In this optimal prognostic model, ADRA1B, CD99L2, EZR, IYD, RGS9BP, and SLC16A2 were associated with high risk, while DUS1L, KIT, MS4A1, PI3, and SUSD2 were correlated with low risk. By calculating the risk score and combining respective overall survival time and survival status, we found that the high-risk group had statistically worse prognosis than the low-risk one. Conclusion Eleven optimal genes from PMPs-related prognostic genes to establish and validate a prognostic model for luminal breast cancer was screened out, which may be an effective and useful prognostic model for patients with luminal breast cancer.

Key words: plasma membrane proteins, prognostic model, luminal breast cancer, TCGA, GEO

摘要： 目的 Luminal型乳腺癌是最常见的一种乳腺癌分子亚型,构建有效的预后模型与寻找有效的治疗靶点对luminal型乳腺癌患者有重要的临床意义。胞膜蛋白（PMPs）在肿瘤的发生发展中发挥着重要作用,本研究着力于构建PMPs相关预后模型,并在此基础上探索可能的治疗靶点。方法从TCGA数据库中下载luminal型乳腺癌的转录组测序数据及临床信息作为训练集,通过筛选差异表达PMPs基因,运用预后相关基因构建PMPs预后模型。同时从GEO数据库中下载相关数据,以验证本研究中所构建模型的效能。结果在建构的预后模型中,ADRA1B、CD99L2、EZR、IYD、RGS9BP和SLC16A2基因高表达与预后负相关,而DUS1L、KIT、MS4A1、PI3和SUSD2基因的表达则与预后正相关。通过所构建的模型计算出各患者的风险评分,并结合其总生存时间和生存状态,发现高风险组患者的预后均较差。结论从PMPs预后基因中筛选出11个可用于建立luminal型乳腺癌预后模型的最佳基因,这个模型可能为临床上luminal型乳腺癌患者提供有效的预后预测。

关键词: 胞膜蛋白, luminal型乳腺癌, 预后模型, TCGA, GEO

CLC Number:

R737.9

ZHU Zhao-wen, JIA Wei-juan, LIU Jie-qiong. A novel plasma membrane proteins-related prognostic model for luminal breast cancer[J]. Lingnan Modern Clinics In Surgery, 2021, 21(03): 281-286.

朱钊雯, 贾卫娟, 刘洁琼. Luminal型乳腺癌胞膜蛋白相关预后模型的构建与验证[J]. 岭南现代临床外科, 2021, 21(03): 281-286.

References

[1] LiJ, Xu JW, Li LH, et al. MGAT3-mediated glycosylation of tetraspanin CD82 at asparagine 157 suppresses ovarian cancer metastasis by inhibiting the integrin signaling pathway[J]. Theranostics, 2020, 10(14):6467-6482.
[2] Evnouchidou I, Chappert P, Benadda S, et al.IRAP-dependent endosomal T cell receptor signalling is essential for t cell responses[J]. Nat Commun, 2020, 11(1):2779.
[3] Simón L, Campos A, Leyton L, Quest AFG.Caveolin-1 function at the plasma membrane and in intracellular compartments in cancer[J]. Cancer Metastasis Rev, 2020, 39(2):435-453.
[4] Costa B, Amorim I, Gärtner F, Vale N.Understanding Breast Cancer: From Conventional Therapies to Repurposed Drugs[J]. Eur J Pharm Sci, 2020, 151:105401.
[5] Vikram R, Chou WC, Hung SC, Shen CY.Tumorigenic and metastatic role of CD44-/low/CD24-/lowcells in luminal breast cancer[J]. Cancers (Basel), 2020, 12(5):1239.
[6] Leth-Larsen R, Lund RR, Ditzel HJ.Plasma membrane proteomics and its application in clinical cancer biomarker discovery[J]. Mol Cell Proteomics, 2010, 9(7):1369-1382.
[7] Llovet JM, Villanueva A, Lachenmayer A, Finn RS.Advances in targeted therapies for hepatocellular carcinoma in the genomic era[J]. Nat Rev Clin Oncol, 2015, 12(8):436.
[8] Zhu Y, Choi SH, Shah K.Multifunctional receptor-targeting antibodies for cancer therapy[J]. Lancet Oncol, 2015, 16(15):e543-e554.
[9] Kale VP, Amin SG, Pandey MK.Targeting ion channels for cancer therapy by repurposing the approved drugs[J]. Biochim Biophys Acta, 2015, 1848(10 Pt B):2747-2755.
[10] Sugie T.Immunotherapy for Metastatic Breast Cancer[J]. Chin Clin Oncol, 2018, 7(3):28.
[11] Powe DG, Voss MJ, Habashy HO, et al.Alpha- and beta-adrenergic receptor (AR) protein expression is associated with poor clinical outcome in breast cancer: an immunohistochemical study[J]. Breast Cancer Res Treat, 2011, 130(2):457-463.
[12] Bixel MG, Li H, Petri B, et al.CD99 and CD99L2 act at the same site as, but independently of, PECAM-1 during leukocyte diapedesis[J]. Blood, 2010, 116(7):1172-1184.
[13] Zhu Y, Zhu MX, Zhang XD, et al.SMYD3 Stimulates EZR and LOXL2 transcription to enhance proliferation, migration, and invasion in esophageal squamous cell carcinoma[J]. Hum Pathol, 2016, 52:153-163.
[14] Zhan XH, Jiao JW, Zhang HF, et al.LOXL2 upregulates phosphorylation of ezrin to promote cytoskeletal reorganization and tumor cell invasion[J]. Cancer Res, 2019, 79(19):4951-4964.
[15] Xie JJ, Xu LY, Xie YM, et al.Roles of Ezrin in the Growth and Invasiveness of Esophageal Squamous Carcinoma Cells[J]. Int J Cancer, 2009, 124(11):2549-2558.
[16] Qureshi-Baig K, Kuhn D, Viry E, et al.Hypoxia-induced autophagy drives colorectal cancer initiation and progression by activating the PRKC/PKC-EZR (Ezrin) pathway[J]. Autophagy, 2019, 16(8):1436-1452.
[17] Lu C, Fang S, Weng Q, et al.Integrated analysis reveals critical glycolytic regulators in hepatocellular carcinoma[J]. Cell Commun Signal, 2020, 18(1):97.
[18] Agenès F, Bosco N, Mascarell L, et al.Differential expression of regulator of G-protein signalling transcripts and in vivo migration of CD4+ naive and regulatory T cells[J]. Immunology, 2005, 115(2):179-188.
[19] Prusinkiewicz MA, Gameiro SF, Ghasemi F, et al.Survival-Associated Metabolic Genes in Human Papillomavirus-Positive Head and Neck Cancers[J]. Cancers (Basel), 2020, 12(1):253.
[20] Medeiros B, Goodale D, Postenka C, et al.Triple-Negative Primary Breast Tumors Induce Supportive Premetastatic Changes in the Extracellular Matrix and Soluble Components of the Lung Microenvironment[J]. Cancers (Basel), 2020, 12(1):172.
[21] Myburgh R, Kiefer JD, Russkamp NF, et al.Anti-human CD117 CAR T-cells efficiently eliminate healthy and malignant CD117-expressing hematopoietic cells[J]. Leukemia,2020, 34(10):2688-2703.
[22] Guo W, Shao F, Sun S, et al.Loss of SUSD2 expression correlates with poor prognosis in patients with surgically resected lung adenocarcinoma[J]. J Cancer, 2020, 11(7):1648-1656.
[23] Watson AP, Evans RL, Egland KA.Multiple functions of sushi domain containing 2 (SUSD2) in breast tumorigenesis[J]. Mol Cancer Res, 2013, 11(1):74-85.
[24] Wang F, Tang C, Gao X, Xu J.Identification of a six-gene signature associated with tumor mutation burden for predicting prognosis in patients with invasive breast carcinoma[J]. Ann Transl Med, 2020, 8(7):453.
[25] Lin QG, Liu W, Mo YZ, et al.Development of prognostic index based on autophagy-related genes analysis in breast cancer[J]. Aging (Albany NY), 2020, 12(2):1366-1376.